爵士制药(JAZZ)今日盘中大涨5.05%,主要受到一则分析师报告的利好推动。
据报道,摩根士丹利维持了对爵士制药的"增持"投资评级,并将其目标价从200美元上调至209美元。分析师预计,公司将凭借其在治疗性领域的领先地位,持续推动业绩增长。
作为一家专注于治疗复杂疾病的生物制药公司,爵士制药在治疗睡眠障碍、癫痫等领域均占据领先地位。随着管线产品的逐步获批上市,分析师认为公司有望保持良好的增长势头。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.